Portfolio
2
companies
OXcan
Oxford Cancer Analytics develops blood tests for early cancer detection.
Oxford Cancer Analytics
Oxford Cancer Analytics develops blood tests for early cancer detection using proteomics and artificial intelligence.
The round was led by We Venture Capital and Cross-Border Impact Ventures to support the development of liquid biopsy tests.
"The power of the OXcan proteomics biomarker discovery platform and the data generated by Oxcan stand out against the backdrop of other liquid biopsy companies, indicating a truly superior performance in the identification of early stage lung cancer"
The round was led by We Venture Capital and Cross-Border Impact Ventures to fund the global commercialisation of its liquid biopsy technology.
"Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy. Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes."